ISA Pharmaceuticals to Present First Clinical Trial Data from the Phase II Study of ISA101b and Cemiplimab Combination in Head and Neck Cancer at the ASCO Annual Meeting 2023
Recommended
ISA Pharmaceuticals to Present First Clinical Trial Data from the Phase II Study of ISA101b and Cemiplimab Combination in Head and Neck Cancer at the ASCO Annual Meeting 2023
In this clinical trial, patients with recurrent and/or metastatic HPV16 positive OPC who experienced disease progression during or within 6 months after prior anti-PD1 therapy were to be treated until disease progression or withdrawal.
Access the full press release to read more here.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->